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The modern era has brought an appreciation that renal cell carcinoma (RCC) includes diverse subtypes derived from 
the various parts of the nephron, each with its distinctive genetic basis and tumor biology. Carcinoma of the collecting 
ducts of Bellini (CDC) is a rare subtype of RCC, with a predictably poor prognosis. This rare subtype represents less than 
1% of all kidney carcinomas. It derives from presumably numerous chromosomal losses. It is of chief importance to 
differentiate CDC from other types of renal cell cancer. Typically, it is characterized by a firm, centrally located tumor 
with infiltrative borders. Regarding the histopathologic characteristics, we can find complex, highly infiltrative cords 
with inflamed (desmoplastic) stroma, with high-grade nuclei and mitoses. Most reported cases of CDC had been high 
grade, advanced stage, and unresponsive to conventional therapies. This rare form of disease highlights the importance 
of multidisciplinary teams in the management of cancer patients. 
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CASE REPORT
We report the case of an apparently healthy 
female patient, in her third decade of life, without 
comorbidities, who developed severe low back pain. 
During the laboratory workup, the abdominal computed 
tomography (CT) demonstrated a 140-millimeter lower-
left renal mass involving the renal medulla and sinus, 
with heterogeneous contrast enhancement, suggestive 
of malignancy. The complete staging failed to show 
distant disease. A nephrectomy was undertaken 
(Figure 1A and 1B). The histology was suggestive of 
Bellini duct carcinoma (Figure 2A and 2B).
DISCUSSION
Collecting duct (Bellini duct) carcinoma (CDC) is 
a histological variant of renal malignancy originating 
in the duct of Bellini of the kidney. CDC has been 
described by numerous synonyms like Bellini duct 
carcinoma, medullary renal carcinoma. CDC constitutes 
only 1% of all RCC.1
In 1986, Fleming and Lewi2 described the CDC as 
a medially located, highly aggressive tumor with mixed 
solid and tubulopapillary patterns, and an infiltrating 
tubular component eliciting a marked desmoplastic 
reaction. This morphology led to the establishing of 
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Bellini duct carcinoma as a distinct type of RCC in 
literature.
Typical CT findings of CDC include medullary 
location, heterogeneous and weak enhancement, 
renal sinus involvement, infiltrative growth, maintained 
renal contour, and a cystic component. However, 
these findings are not specific, and histopathology is 
mandatory for a precise diagnosis.3
CDC typically affects younger patients and often 
presents nonspecific features such as hematuria, flank 
pain, a palpable abdominal mass, or distant metastasis. 
Radical nephrectomy and regional lymphadenectomy 
are commonly adopted in the management of the 
CDC. These tumors present highly aggressive behavior 
and a tendency for early distant metastasis with a 
poor median survival, even after surgical therapeutic 
attempts.4
Most cases are metastatic at presentation. 
Several treatment protocols, including chemotherapy, 
radiotherapy, and immunotherapy, have been 
considered. However, these protocols do not 
demonstrate a favorable response in most CDC 
patients. At present, the Gemcitabine-Cisplatin regimen 
is considered the first-line systemic treatment in 
metastatic CDC as no other specific chemotherapeutic 
agent has demonstrated a beneficial effect. The role 
of targeted therapy in the management of CDC has 
not been established yet, but it may benefit from the 
limited data available to date.5
Reflecting the fact that collecting duct carcinoma 
may share features in common with urothelial 
carcinoma, patients with advanced collecting duct 
carcinoma have responded to cisplatin- or gemcitabine-
Figure 1. Gross view of the Left renal mass (14 × 13 × 14.5 cm) (A) and the surgical site post nephrectomy – 
(1) Vena cava; (2) Sectioned left renal vein; (3) Right renal vein; (4) Descending colon; (5) Psoas muscle (B).
Figure 2. Photomicrograph of the tumor. A – Tumor of medullary localization with tubular morphology, invasive 
pattern and desmoplastic response of the stroma (HE 100x); B – Neoplastic cells with eosinophilic cytoplasm, large, 
vesicular and pleomorphic nuclei with proeminent nucleoli. (HE, 200x).
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based chemotherapy. Multimodality therapy, including 
surgery, systemic therapy, and possibly radiation 
therapy appears to improve survival compared with 
nephrectomy alone for metastatic disease. Early 
reports of VEGF-targeted agents’ use and checkpoint 
inhibitors for this aggressive cancer indicate potential 
clinical benefit.6
An aspect of fundamental importance is the 
correct histological characterization concerning other 
types of renal cell carcinomas, so it is imperative 
to review the slide in young patients with kidney 
cancer. Small collecting duct carcinomas can arise in 
a medullary pyramid, but most are large, infiltrative 
masses, and extension into the cortex is common. 
On microscopic examination, these tumors consist 
of an admixture of dilated tubules and papillary 
structures typically lined by a single layer of cuboidal 
cells, often creating a cobblestone appearance. These 
have predominantly tubular architecture and marked 
desmoplasia. Positivity for E-cadherin and c-KIT helps 
to differentiate this entity from aggressive papillary 
RCC. Other positive stains include PAX8 and Mucin, 
and these can help differentiate CDC from urothelial 
carcinoma, as these stainings are usually negative 
in urothelial carcinoma. Differential diagnosis often 
demands a careful examination of multiple sections.1,7,8
CONCLUSION
Although collecting duct (Bellini duct) tumors 
are rare, they tend to occur in younger patients 
and are frequently aggressive, with similar biologic 
features with urothelial carcinoma. Newer therapeutic 
modalities need to be explored and developed to 
improve the prognosis of these patients. Thus, the 
need for prompt detection and multimodal treatment 
may be the best strategy to achieve better outcomes 
in these patients in the current scenario.
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